Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.

@article{Tedeschini2011PlacebocontrolledAC,
  title={Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.},
  author={Enrico Tedeschini and Maurizio Fava and George I. Papakostas},
  journal={The Journal of clinical psychiatry},
  year={2011},
  volume={72 1},
  pages={98-113}
}
OBJECTIVE In double-blind, randomized, placebo-controlled clinical trials for major depressive disorder (MDD), the impact of study duration on outcome has not been adequately studied. Our aim was to examine whether placebo-controlled antidepressant trials in MDD could be shortened to less than 4 weeks. In order to accomplish this, we examined the relationship between a "positive" or "negative" finding early on (weeks 1-4), and outcome at end point. DATA SOURCES MEDLINE/PubMed publication… CONTINUE READING